VALN - Valneva completes recruitment for late-stage inactivated COVID-19 vaccine trial

Valneva ([[VALN]] -5.0%) announces that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.Over 4K volunteers in the UK have been randomized in the trial, which compares VLA2001 against AstraZeneca’s conditionally approved vaccine, Vaxzevria.The company expects to post topline data by September 2021.Valneva also highlighted that VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

For further details see:

Valneva completes recruitment for late-stage inactivated COVID-19 vaccine trial